Daré Bioscience To Present Clinical Data From A Phase 1 Study Evaluating Sildenafil Cream, 3.6% Investigational Product At The Sexual Medicine Society Of North America Meeting, October 8-11
Daré Bioscience Says It Received Nasdaq Minimum Bid Price Deficiency Notice, Has Until March 29, 2027 To Regain Compliance
Daré Bioscience Receives U.S. Patent For Its Pharmaceutical Compositions Formulated For Topical Application Comprising Lopinavir, Ritonavir To Treat Cervical Pathologies
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript
Daré Bioscience, Inc. (DARE) Discusses Portfolio Advancements and Therapeutic Solutions for Women's Health Transcript
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript
Daré Bioscience, Inc. (DARE) Presents at BIO International Convention 2026 - Slideshow (NASDAQ:DARE) 2026-06-23